Corporate Whistleblowing in Pharma
Add bookmarkCorporate Whistleblowing in Pharma
Add bookmark
Shaul Brazil, a lawyer at BCL Burton Copeland, represented Robert John Dougall, the first executive to be prosecuted by the Serious Fraud Office (SFO) for overseas corruption. The case arose out of corrupt practices in the supply of orthopaedic products by Mr Dougall’s employer, DePuy International Limited, to the public healthcare sector in Greece.
Mr Dougall entered into a “Co-operating Defendant” agreement with the SFO under which he agreed to plead guilty and to assist the SFO and the United States Department of Justice in their investigations and any subsequent prosecutions. This was the first occasion on which the SFO had entered into a “Co-operating Defendant” agreement in an overseas corruption investigation. In return for his assistance, the US authorities entered into a Non-Prosecution Agreement, while in the UK Mr Dougall received a substantially reduced sentence when the Court of Appeal, overturning the decision of the first instance judge, imposed a suspended prison sentence. http://www.bcl.com/notice.php?id=98
In this interview Brazil speaks to Andrea Charles from Pharma IQ, about the possible implications of the UK Bribery Act and how the role of corporate whistleblowers is changing in bribery cases.
[inlinead]